KLOW 80MG
Find your strength. Choose your bundle.
or 4 interest-free payments of $25.00 with afterpay Info
Pre-order · ships November 17–19, 2026
Pre-order details
This is a pre-order item. To keep your order in a single parcel, we ship everything together as soon as it is all in stock, then pack and dispatch within one business day. Availability is shown as an estimated range and may change. Latest estimated availability: November 19, 2026.
- KLOW 80MGShips ~November 17–19, 2026
A closer
look.
KLOW is an advanced multi-peptide formulation developed for high-level scientific research.
Each vial of the KLOW peptide blend delivers a balanced combination of TB-500 (10 mg), BPC-157 (10 mg), GHK-Cu (50 mg), and KPV (10 mg) — four highly regarded research peptides known for their diverse roles in studies involving cellular signalling, tissue dynamics, and inflammatory response pathways.
Research details & references
Last reviewed:
Engineered to Lazarus Labs’ pharmaceutical-grade standards and supplied in Australia, KLOW offers exceptional purity, solubility, and consistency for reproducible laboratory outcomes.
What is KLOW?
Why researchers choose Lazarus Labs
Our proprietary KLOW formulation is independently tested by Janoshik Analytical, with a certificate of analysis available for every batch. Every component undergoes HPLC and LC-MS validation to confirm identity, purity (≥ 99 %), and structural integrity. The result is a stable, well-characterised peptide blend for advanced biochemical and cellular-mechanism research.
Product highlights
- Total Concentration: 80 mg per vial
- Composition: TB-500 (10 mg) · BPC-157 (10 mg) · GHK-Cu (50 mg) · KPV (10 mg)
- Purity: ≥ 99 % (independently verified)
- Solubility: Fully soluble in water (H₂O)
- Testing: every batch independently tested by Janoshik (HPLC + LC-MS)
- Use: Designed for advanced peptide and cellular-mechanism research
Handling & storage
Keep sealed and stored dry at 2–8 °C. Follow your internal laboratory handling and stability procedures after preparation.
Component research overviews
Cited research
- Sikiric P, Hahm KB, Blagaic AB, et al Gut and Liver. 2020. PMID: 31158953.
- Pickart L, Margolina A International Journal of Molecular Sciences. 2018. PMID: 29986520.
- Dalmasso G, et al Gastroenterology. 2008. PMID: 18061177.
Primary literature, verified against PubMed. Cited for scientific reference only — no human-use indication is implied.
The finer
details.
Check the product format, available strengths and intended use.
- Product
- KLOW 80MG
- Intended use
- Laboratory research only
- Documentation
- See COA tab for strength and batch reports
Read the report.
Know the batch.
Compare the product, strength and batch on your vial with the original laboratory document.
Lazarus batch report
- Batch
- LL-KLOW-0125
- Report
- #110533
- Tested
- 2026-08-07
Reports identify tested batches. The available reports do not establish which batch will be dispatched with your order.
WA dispatch.
Tracked delivery.
Orders are dispatched from Western Australia with tracking. Check the selected product's availability and any pre-order notice before ordering.
Pre-order items follow their stated dispatch estimate. Orders containing pre-order items ship together once everything is available.
Delivery times count business days after dispatch, excluding weekends and public holidays, and busy periods can occasionally add one or two business days before dispatch.
Shipping details →



